Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Antonio Ortiz Buijsse"'
Autor:
Esther C.W. Breij, Rob N. de Jong, Paul W.H.I. Parren, Janine Schuurman, Ulf Forssmann, Andreas Lingnau, Richard G. Hibbert, Naomi Hoevenaars, Bart de Jong, Thessa Kroes, Boris S. Vuillermoz, Claudine Vermot-Desroches, Antonio Ortiz Buijsse, Frank J. Beurskens, Kristin Strumane, Marije B. Overdijk
Supplemental Tables Supplemental Figures Supplemental Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fc0742629adc9c9f5ee0bce476596b4
https://doi.org/10.1158/1535-7163.22520991.v1
https://doi.org/10.1158/1535-7163.22520991.v1
Autor:
Esther C.W. Breij, Rob N. de Jong, Paul W.H.I. Parren, Janine Schuurman, Ulf Forssmann, Andreas Lingnau, Richard G. Hibbert, Naomi Hoevenaars, Bart de Jong, Thessa Kroes, Boris S. Vuillermoz, Claudine Vermot-Desroches, Antonio Ortiz Buijsse, Frank J. Beurskens, Kristin Strumane, Marije B. Overdijk
Higher-order death receptor 5 (DR5) clustering can induce tumor cell death; however, therapeutic compounds targeting DR5 have achieved limited clinical efficacy. We describe HexaBody-DR5/DR5, an equimolar mixture of two DR5-specific IgG1 antibodies w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2f853ed6f8830a1d4904eeb661710e2
https://doi.org/10.1158/1535-7163.c.6542862.v1
https://doi.org/10.1158/1535-7163.c.6542862.v1
Autor:
Andreas Lingnau, A. Kate Sasser, Bart de Jong, Marije B. Overdijk, Naomi Hoevenaars, Kristin Strumane, Rob N. de Jong, Paul W. H. I. Parren, Janine Schuurman, Thessa Kroes, Ulf Forssmann, Frank J. Beurskens, Antonio Ortiz Buijsse, Esther C.W. Breij, Claudine Vermot-Desroches
Publikováno v:
Cancer Research. 79:2391-2391
Hyperclustering of Death Receptor 5 (DR5) after binding of its ligand TRAIL induces apoptosis. Targeting DR5 with agonistic antibodies has been evaluated for the treatment of cancer, however clinical efficacy of conventional DR5-targeting monoclonal
Autor:
Paul W. H. I. Parren, Antonio Ortiz Buijsse, Wim K. Bleeker, Sandra Verploegen, Jeanette H. W. Leusen, Tom Vink, Marije B. Overdijk
Publikováno v:
The Journal of Immunology. 189:3430-3438
Development of human therapeutic Abs has led to reduced immunogenicity and optimal interactions with the human immune system in patients. Humanization had as a consequence that efficacy studies performed in mouse models, which represent a crucial ste
Autor:
Fred Shiau, Patrick Liu, Antonio Ortiz-Buijsse, Louis Boon, Simon Hoffenberg, Jon D. Laman, Mark de Boer, Marcel T. den Hartog
Publikováno v:
Toxicology. 174:53-65
Monoclonal antibody (Mab) 5D12 is a potent antagonist of the CD40-CD40L pathway. This cellular interaction has been validated in a large number of experimental animal models where dys-regulation of the immune system plays a role. Chimeric 5D12 (ch5D1
Autor:
Antonio Ortiz Buijsse, Janine Schuurman, Kristin Strumane, Andreas Lingnau, Paul W. H. I. Parren, Marije B. Overdijk, Claudine Vermot-Desroches, Esther C.W. Breij
Publikováno v:
Cancer Research. 76:592-592
Death receptor 5 (DR5) is a highly interesting tumor target based on the enhanced sensitivity of cancer cells for DR5-dependent apoptosis. In recent years, multiple therapeutic DR5 antibodies have been evaluated in the clinic for which results howeve
Autor:
Ewald T. J. van den Bremer, Jan G. J. van de Winkel, Aran F. Labrijn, Antonio Ortiz Buijsse, Paul W. H. I. Parren, Rob C. Aalberse, Wim K. Bleeker, Janine Schuurman, Annemiek Y W Verwilligen, Susan J. Thorpe, Chris H. Polman, Joep Killestein
Publikováno v:
Nature biotechnology, 27(8), 767-771. Nature Publishing Group
Nature Biotechnology, 27(8), 767-U122. Nature Publishing Group
Labrijn, A F, Buijsse, A O, van den Bremer, E T J, Verwilligen, A Y W, Bleeker, W K, Thorpe, S J, Killestein, J, Polman, C H, Aalberse, R C, Schuurman, J, Winkel, J G J & Parren, P W H I 2009, ' Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo ', Nature Biotechnology, vol. 27, no. 8, pp. 767-771 . https://doi.org/10.1038/nbt.1553
Nature Biotechnology, 27(8), 767. Nature Publishing Group
Nature Biotechnology, 27(8), 767-771. Nature Publishing Group
Nature Biotechnology, 27(8), 767-U122. Nature Publishing Group
Labrijn, A F, Buijsse, A O, van den Bremer, E T J, Verwilligen, A Y W, Bleeker, W K, Thorpe, S J, Killestein, J, Polman, C H, Aalberse, R C, Schuurman, J, Winkel, J G J & Parren, P W H I 2009, ' Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo ', Nature Biotechnology, vol. 27, no. 8, pp. 767-771 . https://doi.org/10.1038/nbt.1553
Nature Biotechnology, 27(8), 767. Nature Publishing Group
Nature Biotechnology, 27(8), 767-771. Nature Publishing Group
Two humanized IgG4 antibodies, natalizumab and gemtuzumab, are approved for human use, and several others, like TGN1412, are or have been in clinical development. Although IgG4 antibodies can dynamically exchange half-molecules(1), Fab-arm exchange w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfa1647d790aa1bbb357b695ad5c6d7f
https://dspace.library.uu.nl/handle/1874/43881
https://dspace.library.uu.nl/handle/1874/43881
Autor:
Kate Sasser, Marije B. Overdijk, Paul W. H. I. Parren, Niels Kaldenhoven, Grietje Andringa, Jeroen J. Lammerts van Bueren, Danielle Jakobs, Antonio Ortiz Buijsse, Marleen Voorhorst, Parul Doshi, Sanne Hiddingh, Elke Gresnigt, Michel de Weers, Joyce I. Meesters, Luus Wiegman, Marcel Roza
Publikováno v:
van Bueren, J L, Jakobs, D, Kaldenhoven, N, Roza, M, Hiddingh, S, Meesters, J, Voorhorst, M, Gresnigt, E, Wiegman, L, Buijsse, A O, Andringa, G, Overdijk, M B, Doshi, P, Sasser, K, de Weers, M & Parren, P W H I 2014, ' Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79 ', Blood, vol. 124, no. 21, pp. 3474-3474, . https://doi.org/10.1182/blood.V124.21.3474.3474
The CD38 molecule, with its high expression on Multiple Myeloma (MM), is considered a suitable target for antibody therapy of MM. We developed daratumumab (DARA), a human CD38 monoclonal antibody (mAb) with direct and Fc-mediated cell killing activit
Autor:
Peter J. Simons, Irma Joosten, Hans J. P. M. Koenen, Marcel T. den Hartog, Louis Boon, Sijmie Heerkens, Esther Fasse, R J. Joost van Neerven, Antonio Ortiz-Buijsse
Publikováno v:
Transplantation, 78, 10, pp. 1429-38
Transplantation, 78, 1429-38
Transplantation, 78, 1429-38
Contains fulltext : 57237.pdf (Publisher’s version ) (Closed access) Clinical trials designed to achieve tolerance in humans by selectively antagonizing one of the T-cell costimulatory pathways, CD40-CD40L or CD80/CD86-CD28, are pending. However, s
Autor:
Jan Ceuppens, M. van Meurs, Erwin L. A. Blezer, Jan Bauer, Bert A. 't Hart, Herbert P.M. Brok, Louis Boon, Antonio Ortiz-Buijsse, Jon D. Laman, Seema Ramdien-Murli, M.M. Schellekens, M de Boer
Publikováno v:
Journal of Immunology, 167, 2942-2949. American Association of Immunologists
Jan Bauer
Scopus-Elsevier
Jan Bauer
Scopus-Elsevier
Inhibition of CD40-CD40 ligand interaction is a potentially effective approach for treatment of autoimmune diseases, such as multiple sclerosis. We have investigated this concept with a chimeric antagonist anti-human CD40 mAb (ch5D12) in the marmoset
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e9b2567267664579c772d9be0f7edf6
https://pure.eur.nl/en/publications/71998472-e320-4030-a571-527b836e0c71
https://pure.eur.nl/en/publications/71998472-e320-4030-a571-527b836e0c71